Aetna Updates CPB 1068: Afamitresgene Autoleucel (Tecelra) Coverage Criteria for Synovial Sarcoma
Aetna has modified Clinical Policy Bulletin CPB 1068, which governs coverage of afamitresgene autoleucel (Tecelra) for commercial medical plans, effective March 13, 2026. This T-cell receptor (TCR) therapy targets a rare soft tissue cancer with a narrow, highly specific set of medical necessity criteria—and any billing team working with oncology or sarcoma programs needs to understand the full picture before submitting a claim or prior auth request.
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Afamitresgene Autoleucel (Tecelra) — CPB 1068 |
| Policy Code | CPB 1068 |
| Change Type | Modified |
| Effective Date | 2026-03-13 |
| Impact Level | High |
| Specialties Affected | Medical Oncology, Surgical Oncology, Sarcoma Programs, Cell Therapy/Infusion Centers |
| Key Action | Verify all nine medical necessity criteria and confirm GCIT network designation before scheduling leukapheresis or infusion. |
Aetna CPB 1068: What Is Afamitresgene Autoleucel (Tecelra)?
Tecelra (afamitresgene autoleucel, also known as afami-cel) is an engineered T-cell receptor therapy approved for unresectable or metastatic synovial sarcoma—a rare but aggressive soft tissue malignancy. It's a one-time infusion product, which means billing, auth, and site-of-care logistics are front-loaded and largely unforgiving if done incorrectly.
Aetna, a CVS Health company, has classified Tecelra as a Gene-based, Cellular & Other Innovative Therapies (GCIT®) product under its dedicated GCIT program. That classification triggers a distinct review pathway and site-of-care requirement that differs from standard specialty drug workflows.
Aetna Tecelra Prior Authorization Requirements
Precertification is required for all Aetna participating providers and members in applicable plan designs. This is not optional and cannot be obtained through standard auth channels.
To initiate prior auth for Tecelra, contact Aetna's National Medical Excellence (NME) program directly at 877-212-8811. Do not route this through your standard precertification line—NME handles high-complexity therapies and the review process is managed separately.
Additionally, unless the member's health plan has specifically opted out, Tecelra must be administered at an Aetna Institutes® GCIT Designated Center. Verify your facility's designation status before scheduling any part of the treatment process, including leukapheresis.
Aetna Medical Necessity Criteria for Tecelra (Synovial Sarcoma)
This is where billing teams and RCM directors need to pay close attention. Aetna's CPB 1068 lists nine criteria that must all be met for Tecelra to be considered medically necessary. A failure on any single criterion means denial.
The member must meet all of the following:
| # | Covered Indication |
|---|---|
| 1 | Prior chemotherapy — The member has received prior treatment with chemotherapy. |
| 2 | HLA allele positivity — The tumor is positive for HLA-A*02:01P, HLA-A*02:02P, HLA-A*02:03P, or HLA-A*02:06P. |
| 3 | MAGE-A4 antigen expression — The tumor expresses the MAGE-A4 antigen (confirmed by testing). |
| 4 | Treatment naïve to Tecelra — The member has not received a prior dose of afamitresgene autoleucel. |
| 5 | HLA-A*02:05P negative — The member is not heterozygous or homozygous for HLA-A*02:05P. |
| 6 | ECOG performance status 0 or 1 — Functional status must be documented. |
| 7 | Adequate cardiac and kidney function — Stable and adequate baseline organ function required; note that CPT 80069 (renal function panel) is listed as a related code, suggesting Aetna expects this documentation. |
| 8 | No prior allogeneic HSCT — The member must not have undergone an allogeneic hematopoietic stem cell transplant. |
| 9 | No active infection or inflammatory disorder — Clinically significant active infections or inflammatory conditions are disqualifying. |
All other indications are explicitly considered experimental, investigational, or unproven under this policy.
Continuation of Therapy
Because Tecelra is a one-time dose, Aetna's policy defers continuation criteria to the product's dosage and administration guidance. In practical terms, there is no ongoing auth cycle for re-dosing—but your team should document treatment administration thoroughly for audit purposes, as a single-dose therapy billed multiple times would trigger scrutiny.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
Affected Codes
Covered HCPCS Code (if selection criteria are met)
| Code | Type | Description |
|---|---|---|
| Q2057 | HCPCS | Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose |
Relevant ICD-10-CM Diagnosis Codes (Synovial Sarcoma)
| Code | Description |
|---|---|
| C49.0 | Malignant neoplasm of connective and soft tissue, head, face, and neck |
| C49.1 | Malignant neoplasm of connective and soft tissue, upper limb |
| C49.2 | Malignant neoplasm of connective and soft tissue, lower limb |
| C49.3 | Malignant neoplasm of connective and soft tissue, thorax |
| C49.4 | Malignant neoplasm of connective and soft tissue, abdomen |
| C49.5 | Malignant neoplasm of connective and soft tissue, pelvis |
| C49.6 | Malignant neoplasm of connective and soft tissue, trunk, unspecified |
| C49.7 | Malignant neoplasm of connective and soft tissue, unspecified |
| C49.8 | Malignant neoplasm of overlapping sites of connective and soft tissue |
| C49.9 | Malignant neoplasm of connective and soft tissue, unspecified |
The appropriate C49.x code should reflect documented tumor location and align with pathology and imaging reports submitted with the prior auth.
What Your Billing Team Should Do
| # | Action Item |
|---|---|
| 1 | Contact NME immediately for any active Tecelra candidates. Call 877-212-8811 to initiate the precertification process through Aetna's National Medical Excellence program—standard auth portals will not work for this therapy. Do this before leukapheresis is scheduled. |
| 2 | Confirm GCIT network designation for your facility. Check the Aetna Institutes® GCIT Designated Centers list before any clinical steps begin. If your facility is not designated, the claim will not be covered regardless of medical necessity criteria being met. |
| 3 | Build a nine-point documentation checklist for every Tecelra candidate. All nine medical necessity criteria—prior chemo, HLA allele status, MAGE-A4 expression, treatment naïvety, HLA-A*02:05P negativity, ECOG 0-1, organ function, no prior allogeneic HSCT, and no active infection—must be documented in the auth submission. Missing even one will result in denial. |
| 4 | Order and document the renal function panel (CPT 80069) proactively. Aetna's policy references this code in connection with Tecelra workup, and adequate kidney function is explicitly a coverage criterion. Have that documentation in the record before submitting. |
| 5 | Use HCPCS code Q2057 for the product itself. This code covers leukapheresis and dose preparation in addition to the therapeutic dose—do not attempt to bill those components separately. |
| 6 | Flag this policy change in your RCM system now. With an effective date of March 13, 2026, any claims submitted on or after that date for Tecelra must be evaluated against the updated CPB 1068 criteria. |
Get the Full Picture for CPT 80069
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.